ÂÜÀòÂÒÂ×

Henrijette Richter currently serves as Managing Partner and Partner at Sofinnova Partners since September 2014. In addition to their role at Sofinnova, Henrijette is a Board Member for multiple companies, including Mozart Therapeutics, Inc., Nitrase Therapeutics, Muna Therapeutics, Twentyeight-Seven Therapeutics, and NodThera Limited, where Henrijette also holds the position of Chair of the Board of Directors. Previously, Henrijette was a Board Member for Comet Therapeutics and Karolinska Development. Henrijette's educational background includes an Executive Course in Venture Capital and Private Equity from Harvard Business School, an Executive Certificate in Business Administration from Copenhagen Business School, and advanced degrees in Oncology and Molecular Biology from the Massachusetts Institute of Technology and the University of Copenhagen, respectively.